Drug Research

The first gene therapy for non-muscle invasive bladder cancer (NMIBC) in individuals with high-risk carcinoma in situ (CIS) with or without papillary tumours has been licenced by the US Food and Drug Administration (FDA) as Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin,...

The agency that suggests which medications should be allowed in Europe has backed five new ones, including a gene therapy for haemophilia, a combo treatment for liver cancer, and a drug for the uncommon condition known as Pompe disease. The...

The World Health Organization (WHO) has released its revised consolidated recommendations for treating drug-resistant tuberculosis (DR-TB), which include significant advancements in the treatment options available to individuals with MDR or RR-TB: multidrug-resistant or rifampicin-resistant tuberculosis) and a regimen that...

The global Alzheimer's therapeutics market is anticipated to develop at a compound annual growth rate (CAGR) of 9.3% and reach $6.8 billion by 2032, according to a report by Future Market Insights (FMI). According to the estimate, the global market for...

Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions of this product to enter the market. Often presenting a more cost-effective alternative, biosimilars can provide greater access to...

Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of the Company’s commitment to bring clinical trials closer to the...

Hovione and GEA announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner...